Biomarin Pharmaceutical Inc annual gross profit for fiscal TTM was $2.6 billion, an increase of 3.6% from $2.5 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $2.6B | $2.5B | $2.3B | $1.9B | $1.6B | $1.4B | $1.3B | $1.3B | $1.2B | $1.1B | $907M | $738M | $627M | $460M | $409M | $357M | $306M | $259M | $244M | $103M | $75M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $787M | $571M | $579M | $636M | $675M | $594M | $611M | $557M | $582M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BMRN metrics: Revenue · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All BMRN financial statements → Interactive BMRN charts →
About TickerBase · Data methodology & sources · Privacy · Terms